Natco Pharma Submit New Application with US FDA for Generic Cancer Drug
On Monday, February 13, 2023, Natco Pharma announced that it had submitted a new application to the US health regulator for marketing authorization of the generic version of Olaparib tablets, which are used to treat some types of ovarian, breast, pancreatic, and prostate cancer. The generic version of AstraZeneca’s Olaparib tablets in strengths of 100mg […]
Continue Reading